PMID- 15148526
OWN - NLM
STAT- MEDLINE
DCOM- 20040907
LR  - 20191108
IS  - 0379-0355 (Print)
IS  - 0379-0355 (Linking)
VI  - 26
IP  - 3
DP  - 2004 Apr
TI  - Predicting the clinical course of breast cancer patients undergoing 
      trastuzumab-based therapy: an outlook.
PG  - 201-10
AB  - Her-2/neu overexpressing breast cancer is associated with reduced overall 
      survival, sex steroid receptor negativity and increased resistance to 
      antihormonal therapy, and thus represents a subgroup with poor prognosis. The 
      anti Her-2/neu receptor antibody trastuzumab (Herceptin), however, specifically 
      targets this protein and provides a valuable addition to classical systemic 
      therapies. Unfortunately, not all tumors that express Her-2/neu protein are also 
      adequate candidates for trastuzumab therapy. Therefore, most clinicians now 
      consider Her-2/neu oncoprotein overexpression and/or her-2/neu gene amplification 
      a prerequisite for trastuzumab-based antineoplastic therapy. Nevertheless, due to 
      the relatively low response rates that are observed even in this preselected 
      patient cohort, better response predictors are clearly needed. Here, we review 
      established parameters such as Her-2/neu immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH) and their ability to predict the 
      clinical course of trastuzumab-treated breast cancer. We also evaluate promising 
      parameters such as serum levels of the Her-2/neu extracellular domain (ECD) and 
      the activation status of Her-2/neu oncoprotein (pHer-2/neu), and their use in the 
      clinical setting. Finally, novel tumor-specific such as tumor M2-PK, IGF-IR and 
      p53 are discussed and their potential to predict the efficacy of trastuzumab is 
      assessed.
FAU - Hudelist, G
AU  - Hudelist G
AD  - Division of Special Gynecology, University of Vienna Medical Center, Vienna, 
      Austria.
FAU - Kostler, W
AU  - Kostler W
FAU - Czerwenka, K
AU  - Czerwenka K
FAU - Kubista, E
AU  - Kubista E
FAU - Singer, C F
AU  - Singer CF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Methods Find Exp Clin Pharmacol
JT  - Methods and findings in experimental and clinical pharmacology
JID - 7909595
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 0 (HER-2-derived peptide 884-899)
RN  - 0 (Peptide Fragments)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Biomarkers/blood
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Peptide Fragments/biosynthesis/blood/genetics
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Trastuzumab
RF  - 79
EDAT- 2004/05/19 05:00
MHDA- 2004/09/08 05:00
CRDT- 2004/05/19 05:00
PHST- 2004/05/19 05:00 [pubmed]
PHST- 2004/09/08 05:00 [medline]
PHST- 2004/05/19 05:00 [entrez]
AID - 809727 [pii]
AID - 10.1358/mf.2004.26.3.809727 [doi]
PST - ppublish
SO  - Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):201-10. doi: 
      10.1358/mf.2004.26.3.809727.